Could There Finally Be an Effective Treatment for Alzheimer's Disease?
Source: Streetwise Reports  (11/6/19)
ProMIS' preclinical treatment could possibly outshine Biogen's candidate. More >

Aquestive Therapeutics Shares Up on Pipeline Update and Raised Full-Year 2019 Guidance
Source: Streetwise Reports  (11/6/19)
Aquestive Therapeutics shares traded 20% higher today after the firm reported Q3/19 earnings and raised its FY/19 guidance. The firm states it expects to complete its NDA for Libervant buccal film near the end of this month. More >

Fulgent Genetics Hits 52-Week High After Posting 84% Q3 Revenue Increase
Source: Streetwise Reports  (11/5/19)
Fulgent Genetics shares traded more than 40% higher today after the company reported record revenue in Q3/19. The firm noted that it completed a record 20,697 billable tests in Q3/19, up 272% over the same period last year. More >

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia
Source: Streetwise Reports  (11/4/19)
Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/20. More >

Vancouver Firm Receives Cannabis Flower Sales License, First Order
Source: Streetwise Reports  (11/3/19)
Both of these events are significant achievements for the company. More >

Canadian Tech Firm Lands U.S. Medical Case Management Firm as Client
Source: Streetwise Reports  (11/3/19)
This new partner seeks to employ the company's telemedicine/mobile health system. More >

BeiGene Shares Up 35% on Amgen's $2.7 Billion Investment and China Partnership
Source: Streetwise Reports  (11/1/19)
Shares of BeiGene Ltd. traded 35% higher today to a new a 52-week intraday high after announcing a commercialization agreement for of XGEVA (denosumab), KYPROLIS (carfilzomib), and BLINCYTO (blinatumomab) with Amgen Inc. in China. As part of the partnership, Amgen will invest $2.7 billion in BeiGene for 20.5% equity ownership. More >

Tech Firm Partners With Pharmacy, Diabetes Management Entities
Source: Streetwise Reports  (10/31/19)
The Canadian company will provide its remote patient monitoring and chronic care management software solutions to these two U.S. enterprises. More >

Navidea Shares Jump 60% on Phase 2b Rheumatoid Arthritis Trial Results
Source: Streetwise Reports  (10/29/19)
Shares of Navidea Biopharmaceuticals traded 60% higher today on extremely high relative volume after the firm released data from its Phase 2b Rheumatoid Arthritis Tc 99m Tilmanocept Planar Imaging study. More >

New Data Could Drive Use of Pancreatic Cancer Early Detection Test
Source: Streetwise Reports  (10/29/19)
The recent results and their implications are provided in an H.C. Wainwright & Co. report. More >

Tech Firm Releases Telemedicine Product Aiding Senior Care, Safety
Source: Streetwise Reports  (10/28/19)
The package encompasses wearable devices, two-way video communication and geofencing. More >

IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data
Source: Streetwise Reports  (10/28/19)
Shares of IVERIC bio opened nearly 100% higher today after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. More >

ResMed Shares Set 52-Week Intraday High Price After Posting Q1 Earnings
Source: Streetwise Reports  (10/25/19)
Shares of respiratory medical device maker and software applications company ResMed Inc. traded 15% higher at times today after the firm posted positive Q1/20 earnings results. More >

Varian Shares Trade Higher on Yearly Earnings and FY/20 Guidance
Source: Streetwise Reports  (10/24/19)
Shares of Varian Medical Systems traded 10% higher at times today after the company reported quarterly and annual earnings. The company increased revenue 10% year-over-year and provided FY/20 guidance. More >

Biotech's Topline Phase 3 HER2-Positive Breast Cancer Data 'Impresses'
Source: Streetwise Reports  (10/23/19)
The results and commercial potential of the therapeutic are discussed in an H.C. Wainwright & Co. report. More >

Mobile Health Solutions Provider Adds Clients in Multiple States, Verticals
Source: Streetwise Reports  (10/23/19)
The primary aim of the firm's technology platform is to support remote patient monitoring. More >

Biotech Develops Antibodies Targeting TDP-43 in Neurodegenerative Diseases
Source: Streetwise Reports  (10/23/19)
These therapeutic candidates add to those already in the firm's pipeline. More >

Boston Scientific Reports 13% Q3 Sales Growth and Raises Yearly Estimates
Source: Streetwise Reports  (10/23/19)
This morning shares of Boston Scientific traded 6% higher after the firm reported a 13.1% increase in revenue for Q3/19. The firm also raised its revenue guidance for both Q4/19 and FY/19. More >

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings
Source: Streetwise Reports  (10/22/19)
Shares of Biogen Inc. opened nearly 39% higher today after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also announced Q3/19 earnings today. More >

Clinical Trial Starts for Biopharma's Antifungal in Cryptococcal Meningitis
Source: Streetwise Reports  (10/21/19)
The details of this study and a second one are outlined in a ROTH Capital Partners report. More >

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher
Source: Streetwise Reports  (10/18/19)
Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. More >

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data
Source: Streetwise Reports  (10/17/19)
Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. More >

Healthcare Tech Firm Signs Five New Clients in Texas
Source: Streetwise Reports  (10/16/19)
The company just landed another five clients in Texas and now plans to build out sales teams in five additional states. More >

Achillion Pharma Shares Open 75% Higher After Alexion Buyout Offer
Source: Streetwise Reports  (10/16/19)
Shares of Achillion Pharmaceuticals are trading much higher today after the firm reported that it has agreed to be acquired by Alexion Pharmaceuticals for $930 million, or $6.30 per share in cash, along with the potential for an additional $2 per share if certain other specific clinical trial and regulatory milestones are met. More >

Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho
Source: Streetwise Reports  (10/16/19)
Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close. More >